AFMD - Affimed trades lower following FY bottom-line miss

Affimed ([[AFMD]] -7.8%) FY results:Revenue of €28.4M (+32.7% Y/Y).Operating Loss: (€34.72M) (-7.23%); Net Loss: (€41.37M) (-27.80%); Loss Per Share: (€0.50) (flat Y/Y).Quick Assets: €146.9M, with anticipated cash runway into 2H of 2023.KEY milestones: AFM13 monotherapy, reported positive data from the preplanned interim analysis for the registration-directed trial in PTCL.Announced 100% objective response rate in four response evaluable patients, including 2 complete responses in AFM13 combination with NK cells.AFM24 (phase 1/2a study) completed cohort 4 and is enrolling and treating patients in cohort 5; expansion cohorts expected to start in the second half of 2021.Progress continued, in advancing and forming partnerships with Genentech and Roivant, which triggered payments to Affimed.Previously (Apr.15): Affimed EPS misses by €0.48, beats on revenue.

For further details see:

Affimed trades lower following FY bottom-line miss